

# Andrew M Wardley

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7007801/publications.pdf>

Version: 2024-02-01

143  
papers

17,926  
citations

34100

52  
h-index

16650

123  
g-index

157  
all docs

157  
docs citations

157  
times ranked

15449  
citing authors

#	ARTICLE	IF	CITATIONS
1	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. <i>Lancet, The</i> , 2010, 376, 235-244.	13.7	1,584
2	A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer. <i>New England Journal of Medicine</i> , 2005, 353, 2747-2757.	27.0	1,465
3	2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. <i>Lancet, The</i> , 2007, 369, 29-36.	13.7	1,361
4	Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.. <i>Journal of Clinical Oncology</i> , 1997, 15, 261-267.	1.6	835
5	Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98. <i>Journal of Clinical Oncology</i> , 2007, 25, 486-492.	1.6	835
6	Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3239-3247.	1.6	812
7	Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2â€“Positive, Hormone Receptorâ€“Positive Metastatic Breast Cancer: Results From the Randomized Phase III TANDEM Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 5529-5537.	1.6	746
8	Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. <i>Nature Medicine</i> , 2018, 24, 628-637.	30.7	649
9	Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 1138-1144.	1.6	593
10	Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 1452-1459.	7.0	592
11	Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2âˆ², Node-Positive, High-Risk, Early Breast Cancer (monarchE). <i>Journal of Clinical Oncology</i> , 2020, 38, 3987-3998.	1.6	478
12	Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer. <i>New England Journal of Medicine</i> , 2009, 361, 766-776.	27.0	448
13	Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. <i>British Journal of Cancer</i> , 2004, 91, 639-643.	6.4	362
14	Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8Â·1 years median follow-up. <i>Lancet Oncology, The</i> , 2011, 12, 1101-1108.	10.7	356
15	Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2610-2619.	1.6	331
16	Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole. <i>Journal of Clinical Oncology</i> , 2008, 26, 5569-5575.	1.6	299
17	Randomized Phase II Study of the Antiâ€“Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 2586-2592.	1.6	296
18	AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 1719-1725.	1.6	247

#	ARTICLE	IF	CITATIONS
19	Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. <i>Lancet Oncology</i> , The, 2013, 14, 989-998.	10.7	246
20	6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. <i>Lancet</i> , The, 2019, 393, 2599-2612.	13.7	225
21	Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2 "Negative Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1131-1137.	1.6	214
22	International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1174-1181.	6.3	202
23	Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. <i>British Journal of Cancer</i> , 2009, 100, 684-692.	6.4	196
24	Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. <i>Lancet Oncology</i> , The, 2020, 21, 1296-1308.	10.7	196
25	Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. <i>Lancet Oncology</i> , The, 2013, 14, 72-80.	10.7	192
26	Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 120, 461-467.	2.5	191
27	Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. <i>British Journal of Haematology</i> , 2000, 110, 292-299.	2.5	184
28	Impact of skeletal complications on patients'™ quality of life, mobility, and functional independence. <i>Supportive Care in Cancer</i> , 2008, 16, 879-889.	2.2	175
29	CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). <i>Lancet Oncology</i> , The, 2013, 14, 244-248.	10.7	172
30	Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. <i>Lancet</i> , The, 2009, 373, 1681-1692.	13.7	168
31	Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. <i>Annals of Oncology</i> , 2009, 20, 1489-1498.	1.2	163
32	Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. <i>British Journal of Cancer</i> , 2005, 92, 1869-1876.	6.4	144
33	Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 763-775.	10.7	144
34	Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 1117-1124.	1.6	134
35	Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases " the UK experience. <i>British Journal of Cancer</i> , 2010, 102, 995-1002.	6.4	131
36	Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. <i>Annals of Oncology</i> , 2007, 18, 859-867.	1.2	117

#	ARTICLE	IF	CITATIONS
37	Effectiveness of a Home Care Nursing Program in the Symptom Management of Patients With Colorectal and Breast Cancer Receiving Oral Chemotherapy: A Randomized, Controlled Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 6191-6198.	1.6	116
38	Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTEMIS): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 656-666.	10.7	114
39	Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in <i>HER2</i> -Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 976-983.	1.6	110
40	Effective oral chemotherapy for breast cancer: pillars of strength. <i>Annals of Oncology</i> , 2008, 19, 212-222.	1.2	103
41	A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline <i>BRCA1/2</i> Mutations (ABRAZO). <i>Clinical Cancer Research</i> , 2019, 25, 2717-2724.	7.0	102
42	A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. <i>Supportive Care in Cancer</i> , 2008, 16, 201-208.	2.2	100
43	<i>BRCA1</i> testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. <i>British Journal of Cancer</i> , 2012, 106, 1234-1238.	6.4	85
44	Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or <i>BRCA1/2</i> breast cancer (CRUK/07/012). <i>Cancer Research</i> , 2015, 75, S3-01-S3-01.	0.9	78
45	Circulating Tumor DNA in <i>HER2</i> -Amplified Breast Cancer: A Translational Research Substudy of the NeoALTO Phase III Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3581-3588.	7.0	73
46	Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. <i>Breast Cancer Research</i> , 2011, 13, 209.	5.0	65
47	Facilitating reproductive choices: the impact of health services on the experiences of young women with breast cancer. <i>Psycho-Oncology</i> , 2011, 20, 1044-1052.	2.3	64
48	A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 327-335.	2.5	60
49	PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with <i>HER2</i> positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 506-506.	1.6	59
50	Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2017, 18, 929-945.	10.7	58
51	Postmenopausal advanced breast cancer: Options for therapy after tamoxifen and aromatase inhibitors. <i>Breast</i> , 2006, 15, 584-594.	2.2	57
52	Pathway level alterations rather than mutations in single genes predict response to <i>HER2</i> -targeted therapies in the neo-ALTO trial. <i>Annals of Oncology</i> , 2017, 28, 128-135.	1.2	54
53	Genomic profile of advanced breast cancer in circulating tumour DNA. <i>Nature Communications</i> , 2021, 12, 2423.	12.8	54
54	Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with <i>HER2</i> -positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 1026-1026.	1.6	54

#	ARTICLE	IF	CITATIONS
55	Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline <i>BRCA1/2</i> mutations (ABRAZO).. <i>Journal of Clinical Oncology</i> , 2017, 35, 1007-1007.	1.6	48
56	The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage. <i>British Journal of Cancer</i> , 2009, 101, 582-588.	6.4	46
57	Patient-derived Mammosphere and Xenograft Tumour Initiation Correlates with Progression to Metastasis. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2016, 21, 99-109.	2.7	40
58	Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2). <i>Annals of Oncology</i> , 2005, 16, 1435-1441.	1.2	39
59	Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. <i>European Journal of Cancer</i> , 2017, 82, 237-246.	2.8	38
60	Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. <i>Clinical Trials</i> , 2009, 6, 272-287.	1.6	37
61	Intensive Loading Dose of Trastuzumab Achieves Higher-Than-Steady-State Serum Concentrations and Is Well Tolerated. <i>Journal of Clinical Oncology</i> , 2010, 28, 960-966.	1.6	37
62	Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 1191-1198.	2.5	36
63	Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6year results from the UK TACT trial (CRUK/01/001). <i>European Journal of Cancer</i> , 2014, 50, 2375-2389.	2.8	36
64	Symptoms of endocrine treatment and outcome in the BIG 1-98 study. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 159-169.	2.5	36
65	The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone. <i>British Journal of Cancer</i> , 1998, 78, 774-776.	6.4	35
66	METASTATIC BREAST CANCER: RECOMMENDATIONS PROPOSAL FROM THE EUROPEAN SCHOOL OF ONCOLOGY (ESO)- MBC TASK FORCE. <i>Breast</i> , 2007, 16, 9-10.	2.2	35
67	Triple Negative Breast Cancer: a New Area for Phase III Breast Cancer Clinical Trials. <i>Clinical Oncology</i> , 2008, 20, 35-39.	1.4	34
68	tAnGo: A randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early-stage breast cancer (EBC). <i>Journal of Clinical Oncology</i> , 2008, 26, 506-506.	1.6	26
69	Open label, randomized, phase II study of pertuzumab (P) in patients (pts) with metastatic breast cancer (MBC) with low expression of HER2. <i>Journal of Clinical Oncology</i> , 2005, 23, 3068-3068.	1.6	25
70	Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 1291.	7.1	24
71	Fulvestrant (Faslodex): Clinical experience from the Compassionate Use Programme. <i>Cancer Treatment Reviews</i> , 2005, 31, S10-S16.	7.7	23
72	A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 411-419.	2.5	23

#	ARTICLE	IF	CITATIONS
73	Trastuzumab-associated cardiac events in the Persephone trial. <i>British Journal of Cancer</i> , 2016, 115, 1462-1470.	6.4	23
74	A quantitative histometric murine in vivo model of radiation-induced oral mucositis. <i>Archives of Oral Biology</i> , 1998, 43, 567-577.	1.8	20
75	tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation. <i>British Journal of Cancer</i> , 2008, 99, 597-603.	6.4	20
76	Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature. <i>Cancers</i> , 2020, 12, 3317.	3.7	19
77	Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2017, 18, 755-769.	10.7	18
78	The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 155-165.	2.5	18
79	Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. <i>British Journal of Cancer</i> , 2012, 106, 1618-1625.	6.4	17
80	Overview of the impact of conventional systemic therapies on breast cancer. <i>Endocrine-Related Cancer</i> , 2005, 12, S9-S16.	3.1	15
81	A phase II trial of low-dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to aromatase inhibition. <i>European Journal of Cancer</i> , 2015, 51, 2725-2731.	2.8	15
82	Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge. <i>Cancer Treatment Reviews</i> , 2021, 99, 102229.	7.7	15
83	Role of granulocyte-macrophage colony-stimulating factor in chemotherapy-induced oral mucositis. <i>Journal of Clinical Oncology</i> , 1996, 14, 1741-1743.	1.6	13
84	Emerging Data on Optimal Adjuvant Endocrine Therapy: Breast International Group Trial 1-98/MA.17. <i>Clinical Breast Cancer</i> , 2006, 6, S45-S50.	2.4	13
85	Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer: a cross-sectional study evaluating the relationships between disease and treatment stage. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 353.	2.4	13
86	Capecitabine: Expanding Options for the Treatment of Patients with Early or Locally Advanced Breast Cancer. <i>Oncologist</i> , 2006, 11, 20-26.	3.7	12
87	Randomized phase II study of weekly versus every 3 week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC): Final results. <i>Journal of Clinical Oncology</i> , 2010, 28, 1040-1040.	1.6	12
88	The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 295-306.	2.5	11
89	Six versus 12 months™ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-190.	2.8	11
90	Randomized, Phase III Trial of Sequential Epirubicin and Docetaxel Versus Epirubicin Alone in Postmenopausal Patients With Node-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 3247-3254.	1.6	10

#	ARTICLE	IF	CITATIONS
91	Re: Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer. Journal of the National Cancer Institute, 2009, 101, 1730-1730.	6.3	9
92	Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial). European Journal of Cancer, 2021, 153, 223-233.	2.8	9
93	Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial. Breast Cancer Research and Treatment, 2021, 185, 697-707.	2.5	8
94	Abstract GS3-06: Results from the plasmaMATCH trial: A multiple parallel cohort, multi-centre clinical trial of circulating tumour DNA testing to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010)., 2020, , .		8
95	Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).. Journal of Clinical Oncology, 2020, 38, 1005-1005.	1.6	8
96	Fatal fungaemia in a leukaemic patient receiving fluconazole prophylaxis. Journal of Infection, 1996, 33, 43-45.	3.3	7
97	Safety and efficacy of the combination of trastuzumab with docetaxel for HER2-positive women with advanced breast cancer. A review of the existing clinical trials and results of the expanded access programme in the UK. International Journal of Clinical Practice, 2004, 58, 581-586.	1.7	7
98	The need for advanced breast cancer treatment guidelines: Results of an internet-based survey. Breast, 2008, 17, 275-281.	2.2	7
99	ACUFOCIN: Randomized clinical trial of ACUpuncture plus standard care versus standard care alone FOChemotherapy Induced peripheral Neuropathy (CIPN).. Journal of Clinical Oncology, 2020, 38, 12003-12003.	1.6	7
100	Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results. BMC Cancer, 2018, 18, 391.	2.6	6
101	TEXAS (Taxotere® EXperience with Anthracyclines Study) trial: mature results of activity/toxicity of docetaxel given with anthracyclines in a community setting, as first line therapy for MBC. Cancer Chemotherapy and Pharmacology, 2006, 59, 413-418.	2.3	5
102	Understanding the BIG results: Insights from the BIG 1-98 trial analyses. Advances in Therapy, 2008, 25, 1257-1275.	2.9	4
103	Emerging targeted combinations in the management of breast cancer. Breast Cancer: Targets and Therapy, 2013, 5, 61.	1.8	4
104	A time-in-motion study of oral ibandronate versus iv zoledronic acid for treatment of metastatic bone disease in breast cancer patients. Journal of Clinical Oncology, 2005, 23, 6123-6123.	1.6	4
105	First-line pertuzumab (P), trastuzumab (H), and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC): Interim safety results (N=704) from PERUSE.. Journal of Clinical Oncology, 2014, 32, 548-548.	1.6	4
106	PERSEPHONE: Duration of trastuzumab with chemotherapy in patients with HER2-positive early breast cancer – Six versus twelve months.. Journal of Clinical Oncology, 2014, 32, TPS656-TPS656.	1.6	4
107	B-PRECISE-01 Study: A phase Ib trial of MEN1611, a PI3K Inhibitor, combined with trastuzumab ± fulvestrant for the treatment of HER2-positive advanced or metastatic breast cancer.. Journal of Clinical Oncology, 2019, 37, TPS1101-TPS1101.	1.6	4
108	Abstract P1-19-17: Dose escalation and expansion study of lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed with no drug holiday in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer. Cancer Research, 2020, 80, P1-19-17-P1-19-17.	0.9	4

#	ARTICLE	IF	CITATIONS
109	Letrozole: Advancing Hormone Therapy in Breast Cancer. <i>Women's Health</i> , 2012, 8, 611-618.	1.5	3
110	Clinical behavior of recurrent hormone receptorâ€“positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1â€“98 clinical trial. <i>Cancer</i> , 2021, 127, 700-708.	4.1	2
111	Abstract PS5-02: Assessment of early ctDNA dynamics to predict efficacy of targeted therapies in metastatic breast cancer: Results from plasmaMATCH trial. , 2021, , .		2
112	A phase 2 study (2-stage, 2-cohort) of the oral PARP inhibitor talazoparib (BMN 673) in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS1108-TPS1108.	1.6	2
113	Does HER2 overexpression affect response to endocrine therapy in advanced cancer?. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 78-79.	4.3	1
114	2105 POSTER An accelerated loading regimen for trastuzumab leads to early higher than steady-state serum concentrations. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 215.	2.2	1
115	21. Experience with the oncotype DX Assay in a UK centre. <i>European Journal of Surgical Oncology</i> , 2014, 40, 606-607.	1.0	1
116	53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC BREAST CANCER (MBC) WITH BRAIN METASTASES (BM) (HER2CLIMB). <i>Neuro-Oncology Advances</i> , 2020, 2, ii11-ii11.	0.7	1
117	Abstract PD13-04: Impact of tucatinib on health-related quality of life in patients with HER2+ metastatic breast cancer with stable and active brain metastases. <i>Cancer Research</i> , 2021, 81, PD13-04-PD13-04.	0.9	1
118	Abstract GS3-07: The genomic landscape of breast cancer based on ctDNA analysis: Data from the plasmaMATCH trial. , 2020, , .		1
119	Abstract P1-19-07: Results from plasmaMATCH trial treatment cohort B: A phase II trial of neratinib plus fulvestrant in ER positive breast cancer or neratinib alone in ER negative breast cancer in patients with aHER2mutation identified via ctDNA screening (CRUK/15/010). , 2020, , .		1
120	T-DM1 to induce response in central nervous system (CNS) metastases from Her2 +ve metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 582-582.	1.6	1
121	Directing Therapy with Circulating Tumor DNA Analysis in Advanced Breast Cancer: The PlasmaMATCH Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
122	PCN9 ATIME-IN-MOTION STUDY OF ORAL IBANDRONATE VERSUS IV ZOLEDRONIC ACID FOR THE TREATMENT OF METASTATIC BONE DISEASE IN BREAST CANCER PATIENTS IN THE UK. <i>Value in Health</i> , 2004, 7, 671-672.	0.3	0
123	P-753 Extrapulmonary small cell carcinoma: Our experience over ten years. <i>Lung Cancer</i> , 2005, 49, S317.	2.0	0
124	Second-line treatment of postmenopausal women with advanced breast carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 613-624.	2.4	0
125	Analysis of cardiac events in a single institution series of 155 patients who completed adjuvant Trastuzumab. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 219.	2.2	0
126	289 A randomised controlled trial of a symptom-orientated home care nursing programme in patients with colorectal and breast cancer receiving oral chemotherapy. <i>European Journal of Cancer, Supplement</i> , 2009, 7, 69-70.	2.2	0



#	ARTICLE	IF	CITATIONS
127	PERSEPHONE is a randomised phase III controlled trial comparing six months of trastuzumab to the standard 12 months in patients with HER2 positive early breast cancer. <i>European Journal of Surgical Oncology</i> , 2014, 40, 619.	1.0	0
128	Protective strategies to prevent trastuzumab-induced cardiotoxicity – Authors' reply. <i>Lancet</i> , The, 2020, 395, 492-493.	13.7	0
129	Home versus hospital treatment with Zometa (zoledronic acid) in patients with skeletal metastases secondary to breast cancer - interim analysis of hospital run-in phase. <i>European Journal of Cancer</i> , 2002, 38, S69.	2.8	0
130	Analysis of a single institution series of 155 patients treated with adjuvant trastuzumab. <i>Journal of Clinical Oncology</i> , 2008, 26, 11504-11504.	1.6	0
131	Polymorphisms of the aromatase gene (CYP19A1) and benefit of aromatase inhibitors (AIs) in metastatic breast cancer (mBC) patients.. <i>Journal of Clinical Oncology</i> , 2011, 29, 608-608.	1.6	0
132	PERSEPHONE: Duration of trastuzumab with chemotherapy in women with HER2-positive early breast cancer – Six versus twelve months.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS667-TPS667.	1.6	0
133	Abstract OT1-1-08: PERSEPHONE: Duration of trastuzumab with chemotherapy in women with HER-2+ve early breast cancer. , 2013, , .		0
134	Cardiology monitoring substudy in the PERSEPHONE trial: 6 versus 12 months of trastuzumab.. <i>Journal of Clinical Oncology</i> , 2014, 32, 552-552.	1.6	0
135	Eribulin for advanced breast cancer: Clinical experience in the real world.. <i>Journal of Clinical Oncology</i> , 2014, 32, e12003-e12003.	1.6	0
136	Abstract P2-06-02: Breast cancer stem-like cell activity correlates with tumour progression to metastasis but not with clinical or tumour characteristics. , 2015, , .		0
137	Abstract P4-18-03: IBCSG BIG 1-98 study: The long-term follow-up experience. , 2015, , .		0
138	Real-world experience of exemestane-everolimus (EXE-EVE) in elderly patients with hormone-receptor positive (HR+) metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 576-576.	1.6	0
139	Patient's perspective of living with and beyond the treatment of trastuzumab: Results from the PERSEPHONE early breast cancer trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, e22101-e22101.	1.6	0
140	Abstract P1-19-11: Results from plasmaMATCH trial treatment cohort C: A phase II trial of capivasertib plus fulvestrant in ER positive breast cancer patients with an AKT1 mutation identified via ctDNA screening (CRUK/15/010). , 2020, , .		0
141	Abstract P1-19-04: Results from plasmaMATCH trial treatment cohort A: A phase II trial of extended-dose fulvestrant in patients with an ESR1 mutation identified via ctDNA screening (CRUK/15/010). , 2020, , .		0
142	Abstract P1-19-14: Results from plasmaMATCH trial treatment cohort D: A phase II trial of capivasertib in patients with an AKT activation basket mutation identified via ctDNA testing or tumour sequencing (CRUK/15/010). , 2020, , .		0
143	Abstract P3-11-10: Health-related quality of life (HRQoL) in monarchER: Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in HR+, HER2+ advanced breast cancer. , 2020, , .		0